Kyverna Therapeutics is engineering cell therapies for autoimmune and inflammatory diseases. Many autoimmune diseases lack optimal treatment for patients. Through the use of synthetic biology, immunology and cell engineering, Kyverna is using their SmarTcell platform to advance technologies to treat the cause of these diseases. Kyverna’s technologies include chimeric antigen receptor T cells designed to eliminate pathogenic cells in specific organs and tissues. Kyverna is also developing synthetic versions of Regulatory T cells to control immune homeostasis. Current therapies are in clinical trials for B-cell driven autoimmune diseases.